L3VLUP
ProSign in

MDGL in the 13F filings

Madrigal Pharmaceuticals Inc · CUSIP 558868105

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023
Quarter end
31 Dec 2023
the date the book describes
Filed
14 Feb 2024
latest of these filings; the earliest 12 Feb 2024
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2023 and Q4 2023; 3 listed it in both
Shares listed
3,543,896
combined, among listed positions
Reported value
$820m
combined, at the quarter end

Among the 93 comparable managers: 2 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing MDGL in Q4 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
Janus Henderson Group Ltd2,902,050$672m0.40%Trimmed-140,61114 Feb 2024 (the filing on sec.gov)
AllianceBernstein LP339,754$79munder 0.1%Trimmedn.a.14 Feb 2024 (the filing on sec.gov)
Artisan Partners LP296,480$69m0.11%Added+16,39012 Feb 2024 (the filing on sec.gov)
Farallon Capital Management LLC3,319$768kunder 0.1%Held014 Feb 2024 (the filing on sec.gov)
Brevan Howard Capital Management LP2,293$531kunder 0.1%Newnew14 Feb 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2023 to Q4 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
6 in Q3 2024 to 11 in Q2 2026

Tracked managers listing it, at least.

0510152017201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
MDGL by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20161$6.5mn.a.n.a.
Q1 20171$6.7mn.a.n.a.
Q4 20172$14mn.a.n.a.
Q1 20183$128mn.a.n.a.
Q2 20183$421mn.a.n.a.
Q3 20185$410mn.a.n.a.
Q4 20184$194mn.a.n.a.
Q1 20191$208mn.a.n.a.
Q2 20192$182mn.a.n.a.
Q3 20191$145mn.a.n.a.
Q4 20192$160mn.a.n.a.
Q1 20202$119mn.a.n.a.
Q2 20203$259mn.a.n.a.
Q3 20203$311mn.a.n.a.
Q4 20202$234mn.a.n.a.
Q1 20214$281mn.a.n.a.
Q2 20212$67mn.a.n.a.
Q3 20211$18mn.a.n.a.
Q4 20211$19mn.a.n.a.
Q1 20221$22mn.a.n.a.
Q2 20222$21mn.a.n.a.
Q3 20222$14mn.a.n.a.
Q4 20224$204mn.a.n.a.
Q1 20239$384mn.a.n.a.
Q2 20235$589mn.a.n.a.
Q3 20236$579mn.a.n.a.
Q4 20235$820m22
Q1 20248$1.1bn61
Q2 20247$1.1bn34
Q3 20246$788m24
Q4 20246$1.1bn23
Q1 20257$1.2bn33
Q2 20256$961m24
Q3 20259$1.3bn62
Q4 202512$1.8bn1513
Q1 202610$2.2bn1315
Q2 202611$2.3bn1815

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

MDGL and LLY →MDGL and JNJ →MDGL and VRTX →Choose a stock to compare with MDGL →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own MDGL, latest filings →Back to the 13F Explorer →